Norges Bank’s Akebia Therapeutics AKBA Stock Holding History

Norges Bank’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-405,178	Closed	-$1.13M	–	2133
2020 Q4	$1.13M	Sell	405,178 -409,106	-50%	-$1.19M	﹤0.01%	2020
2020 Q3	$2.04M	Sell	814,284 -155,747	-16%	-$1.37M	﹤0.01%	1965
2020 Q2	$13.2M	Buy	970,031 +50,000	+5%	+$517K	﹤0.01%	1637
2020 Q1	$6.97M	Hold	920,031	–	–	﹤0.01%	1740
2019 Q4	$5.82M	Hold	920,031	–	–	﹤0.01%	1891
2019 Q3	$3.61M	Hold	920,031	–	–	﹤0.01%	1945
2019 Q2	$4.45M	Sell	920,031 -161,030	-15%	-$916K	﹤0.01%	1946
2019 Q1	$8.85M	Buy	1,081,061 +448,602	+71%	+$3.08M	﹤0.01%	1843
2018 Q4	$3.5M	Buy	+632,459	New	+$4.95M	﹤0.01%	1961
2018 Q2	–	Sell	-207,173	Closed	-$1.97M	–	2126
2018 Q1	$1.97M	Sell	207,173 -249,400	-55%	-$3.49M	﹤0.01%	1998
2017 Q4	$6.79M	Sell	456,573 -39,833	-8%	-$661K	﹤0.01%	1825
2017 Q3	$9.76M	Buy	496,406 +396,406	+396%	+$6.09M	﹤0.01%	1740
2017 Q2	$1.44M	Buy	+100,000	New	+$1.27M	﹤0.01%	2014
2014 Q3	–	Sell	-30,000	Closed	-$834K	–	2326
2014 Q2	$834K	Buy	+30,000	New	+$722K	﹤0.01%	2186

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's AKBA Position: Q1 2021 in Review

Norges Bank sold out of Akebia Therapeutics (AKBA) in Q1 2021, closing a stake of 405,178 shares — an estimated $1.13M sold.

Norges Bank first reported a position in AKBA in Q2 2014 and held it in 14 quarters. The position peaked at $13.2M in Q2 2020. 145 funds tracked by Wall St. Rank hold AKBA as of Q1 2021.

Norges Bank reported no remaining Akebia Therapeutics position as of Q1 2021 after selling out during the quarter.
Norges Bank sold 405,178 Akebia Therapeutics shares in Q1 2021, an estimated $1.13M.
Norges Bank first reported a position in Akebia Therapeutics in Q2 2014 and held it in 14 quarters.
Norges Bank's Akebia Therapeutics position peaked at $13.2M in Q2 2020.
145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2021.

Based on Norges Bank's 13F filing for Q1 2021, filed 7 May 2021.